Clinical Trial

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown the following criteria: * Participants from the IMG-7289-202/MK-3543-005 (NCT05223920) study must have received at least 6 months of treatment with bomedemstat; * Essential thrombocythemia (ET) and polycythemia vera (PV) participants from studies other than IMG-7289-202/MK-3543-005 must have achieved confirmed hematologic remission. No hypothesis testing will be conducted in this study.
Protocol Amendment History 24 amendments
This ClinicalTrials.gov record has been amended 24 times since 2024-04-02; most recent amendment 2026-04-01.
Status change: Not Yet Recruiting → Recruiting 2024-05-27
Trial Details
NCT Number NCT06351631
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera
Enrollment 400 participants
Start Date 2024-05-23
Primary Completion 2034-12-04 (estimated)
Study Completion 2034-12-04 (estimated)
Updated on ClinicalTrials.gov 2026-04-02